November 26, 2019 06:51 AM EST

Veloxis wins $1.3B buyout, and the new owner plans to follow up with new deals

John Carroll

Editor & Founder

Japan’s Asahi Kasei Pharma has stepped up with a deal to buy out Copenhagen-based Veloxis Pharmaceuticals for $1.3 billion, bagging an organ rejection drug in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Veloxis wins $1.3B buyout, and the new owner plans to follow up with new deals

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Coave raises €32M Series A despite being two years away from the clinic

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Velox­is wins $1.3B buy­out, and the new own­er plans to fol­low up with new deals

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Veloxis wins $1.3B buyout, and the new owner plans to follow up with new deals